CLEOPATRA

NCT00567190 📎

Regimen

Experimental
Pertuzumab + trastuzumab + docetaxel until progression (pertuzumab + trastuzumab continued after docetaxel discontinuation).
Control
Placebo + trastuzumab + docetaxel.

Population

HER2-positive metastatic or locally recurrent breast cancer, no prior chemotherapy or HER2-targeted therapy for metastatic disease.

Key finding

CLEOPATRA made pertuzumab + trastuzumab + taxane the 1L standard for HER2+ MBC and set the OS benchmark (~57 months) for the field. NCCN category 1 preferred regimen pre-2026. Still a valid reference arm now challenged by DESTINY-Breast09.

Source: PMID 22149875

Timeline

  • Publication: 2012 Jan 12

Guideline citations

  • NCCN BREAST